Comments
Intas Pharmaceuticals on Friday announced launching of Razumab, a biosimilar to Lucentis (ranibizumab). It claimed to be the first company globally to develop and launch a biosimilar version of ranibizumab. Razumab will be 25 per cent cheaper than its imported alternate.
Razumab is used for sterile use in the eye and is offered as single dose vial, thus reducing the risk of contamination during use, a statement said here.
"Intas’ ranibizumab, Razumab is a feat achieved by the scientists at Intas and unparalleled till date. With the mission to provide global healthcare at affordable costs, Razumab will be about 25 per cent cheaper than the imported Lucentis in the hand of the patient. This would lead to an annual saving of about Rs 35,000 or more in the cost of treatment to the patient, depending on the number of injections used and the clinical condition of the patient," said Binish Chudgar, the Vice Chairman of the Company in a statement.
Razumab is also manufactured in the same facilities as its other biosimilars.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.